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Abstract
I-mfa (inhibitor of the MyoD family) is a transcription modulator that binds to and suppresses the transcriptional activity
of MyoD family members. I-mfa transcripts are expressed in sclerotome, suggesting a role of I-mfa in skeletogenesis. The aim
of this study was to examine the expression and regulation of I-mfa in osteoblasts. We found that I-mfa is expressed at a low
level in an osteoblast-like cell line, MC3T3E1, and a pluripotent differentiation modulator, 1,25-dihydroxyvitamin D3,
specifically enhanced I-mfa mRNA expression. This effect was completely blocked by the presence of an RNA polymerase
inhibitor, but not by a protein synthesis inhibitor, suggesting that 1,25-dihydroxyvitamin D3 upregulates transcription of the
I-mfa gene without requirement for new protein synthesis. Western blot analysis indicated that 1,25-dihydroxyvitamin D3
increased the I-mfa protein levels severalfold in MC3T3E1 cells. I-mfa expression was also observed in primary mouse
calvaria cells and ROS17/2.8 cells and 1,25-dihydroxyvitamin D3 enhanced I-mfa expression in these cells. These data
indicate that I-mfa is a novel transcriptional regulator gene expressed in osteoblasts and that its level is under the control of
1,25-dihydroxyvitamin D3. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Cell proliferation and di¡erentiation are regulated
by multiple sets of transcription factors. In mesen-
chymal tissue development, basic helix-loop-helix
(bHLH) type transcription factor families play their
pivotal roles in myoblast di¡erentiation [1^3].
HLH family members have also been described to
regulate the osteoblastic phenotype as a part of mul-
tiple types of transcription factors that includes
Cbfa1. Id-1, a negative regulator of bHLH transcrip-
tion factors, is involved in the suppression of osteo-
calcin promoter activity in osteoblasts [4]. Other
bHLH type transcription factors, such as scleraxis,
HES-1, and ADD1/SREBP1 are also expressed in
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osteoblastic cells [5^8]. Scleraxis overexpression in
ROS17/2.8 cells appears to alter the fate of osteo-
blastic cells to become chondrogenic by upregulating
aggrecan gene expression [5,6]. HES-1 is a mamma-
lian homologue of the Drosophila pair rule genes,
hairy and enhancer of split. HES-1 acts as a negative
regulator in neurogenesis while this transcription fac-
tor is also expressed in ROS17/2.8 cells [7].
I-mfa was ¢rst identi¢ed as a cysteine-rich protein
that binds to the bHLH domain of MyoD (amino
acids 57^166) by a yeast two-hybrid system using a
cDNA library prepared from mouse embryo 9.5^10.5
days post coitum (dpc) [9]. This is the time period
when MyoD starts to be expressed. Two other alter-
native splicing isoforms, I-mfb and I-mfc were also
identi¢ed using mouse embryonic cDNA libraries.
Chen et al. showed that I-mfa can interact and in-
hibit the functions of MyoD family members, such as
MyoD, Myf5, and myogenin [9]. In contrast, I-mfb
and I-mfc are not able to bind MyoD family mem-
bers and to inhibit their function. These observations
indicated that I-mfa plays an important role in the
inhibition of myogenesis. Unlike MyoD family mem-
bers, I-mfa transcripts are expressed not in myotome
but in sclerotome in 11.5 dpc mouse embryos, sug-
gesting a possible role of I-mfa in skeletogenesis. In
this study, we showed that I-mfa is expressed in an
osteoblast-like cell line, MC3T3E1, as well as in pri-
mary mouse calvaria cells and that its expression is
enhanced by a pluripotent di¡erentiation modulator,
1,25-dihydroxyvitamin D3.
2. Materials and methods
2.1. Materials
1,25-Dihydroxyvitamin D3 was kindly supplied by
Taisho Pharmaceuticals (Tokyo, Japan). Minimum
essential medium K modi¢cation (K-MEM), F-12 me-
dium and fetal bovine serum (FBS) were purchased
from Gibco BRL (Grand Island, NY, USA). Horse-
radish peroxidase (HRP)-conjugated anti-rabbit IgG
was purchased from Zymed Laboratories (San Fran-
cisco, CA, USA). Transforming growth factor-L
(TGF-L), basic ¢broblast growth factor (FGF), in-
terleukin (IL)-1K, IL-6 and tumor necrosis growth
factor-K (TNF-K) were purchased from RpD Sys-
tems (Minneapolis, MN, USA). 5,6-Dichlorobenzi-
midazole riboside (DRB), cycloheximide (CHX),
dexamethasone, retinoic acid and 12-O-tetradeca-
noylphorbol 13-acetate (TPA) were purchased from
Sigma (St. Louis, MO, USA). Parathyroid hormone
(PTH) (1^34, human) was purchased from Bachem
Feinchemikalien (Switzerland). The human recombi-
nant bone morphogenetic protein 2 (BMP2) homo-
dimer was kindly supplied by the Genetics Institute
(Cambridge, MA, USA).
2.2. Cell culture
Clonal osteoblastic MC3T3E1 cells were kindly
provided by Dr. Kodama (Oh-U University, Japan)
and maintained in K-MEM supplemented with 5%
FBS at 37‡C in a humidi¢ed atmosphere of 5%
CO2. ROS17/2.8 cells were a kind gift from Dr. Ro-
dan (Merck Research Labs.) and were maintained in
modi¢ed F-12 medium containing 5% FBS.
Primary mouse osteoblast-enriched cells were pre-
pared from newborn mouse calvariae as described by
Wong et al. [10]. Brie£y, newborn mouse osteoblast-
enriched cells were prepared by collecting the cells
released between 0 and 35 min at 37‡C during enzy-
matic digestion in phosphate bu¡ered saline contain-
ing 0.15% collagenase (Wako Pure Chemical Indus-
tries, Osaka, Japan). The cells were grown in K-
MEM supplemented with 10% FBS, 100 units/ml
penicillin G and 100 Wg/ml streptomycin sulfate
(Gibco BRL).
To examine the e¡ects of cytokines or hormones
on I-mfa expression, the cells were plated at 3U104
cells/cm2 1 day prior to treatment and the next day
the media were replaced with fresh ones containing
cytokines, hormones or vehicle.
2.3. RNA preparation and Northern blot analysis
Total cellular RNA was extracted according to the
acid guanidine phenol chloroform method [11]. 10 Wg
of total RNA per lane were fractionated in agarose
gel (1% agarose, 20 mM MOPS, pH 7, 5 mM sodium
acetate, 0.5 mM EDTA, 2.3% formaldehyde) and
transferred to nylon membranes (GeneScreen, NEN
Research Products, Boston, MA, USA). The mem-
branes were incubated at 42‡C for 2 days in hybrid-
ization bu¡er (50% formamide, 250 mM sodium
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phosphate pH 7.2, 25 mM sodium chloride, 0.5%
SDS, 0.2 mg/ml sheared herring sperm DNA, 10%
polyethylene glycol MW6000, 10UDenhardt’s solu-
tion (0.4% Ficoll type 400, 0.4% polyvinyl-pyrroli-
done, 0.4% BSA fraction V)). A 380 bp EcoRI-
SphI fragment of murine I-mfa cDNA which con-
tains the N-terminal coding region and can recognize
three alternative splicing forms of I-mf (i.e. I-mfa, I-
mfb, and I-mfc), was labeled with [32P]dCTP using a
BcaBEST random primer labeling kit (Takara Shu-
zo, Tokyo, Japan) and used for hybridization. Hy-
bridization was performed at 42‡C for 24 h in a fresh
hybridization bu¡er containing 1U106 cpm/ml of the
labeled probe. After hybridization, membranes were
rinsed at 60‡C for 40 min in 0.2USSC, 0.5% SDS
solution and exposed to X-ray ¢lm. For the detection
of type I collagen, osteopontin and GAPDH mRNA,
full length cDNA was prepared and labeled as de-
scribed above.
2.4. Semiquantitative RT-PCR
Total RNA was reverse transcribed and ampli¢ed
by a Titan One-Tube RT-PCR kit (Boehringer
Mannheim, Germany). The PCR condition was de-
termined such that the band intensity should be in
linear relationship to the increasing amount of RNA
and PCR cycle number. The bands were quantitated
by densitometry using Bio-Pro¢le Version97 (Vilber
Lourmat, France) and each value was normalized
against that of GAPDH. Primers for I-mfa were 5P-
cagaattcacagcctcaagggaacccc-3P (289^306 bp) and 5P-
acagtatgcagtggacgcagca-3P (538^517 bp). Primers for
GAPDH were 5P-accacagtccatgccatcac-3P (586^605
bp) and 5P-tccaccaccctgttgctgta-3P (1037^1018 bp).
Each number refers to that in each mRNA sequence.
A GeneAmp PCR System 9700 (PE Applied Biosys-
tems, Foster City, CA, USA) was used for gene am-
pli¢cation and the RT-PCR condition was employed
according to the manufacturer’s instructions as fol-
lows. RT reaction: 30 min at 60‡CC2 min at 94‡C;
¢rst PCR (10 cycles): 30 s at 94‡CC30 s at
60‡CC45 s at 68‡C; second PCR (22 cycles): 30 s
at 94‡CC30 s at 60‡CC45 s+5 s/cycle at 68‡C.
2.5. Western blot analysis
Cells were harvested and resuspended in Tris based
cell lysis bu¡er (62.5 mM Tris, pH 6.8, 2% SDS, 10%
glycerol, 5% L-mercaptoethanol) and lysed by soni-
cation on ice. Protein concentrations of total cell
lysates were measured by a Protein Assay kit (Bio-
Rad, CA, USA). 10 Wg of protein per lane were frac-
tionated in acrylamide gel (10% acrylamide, 0.5%
SDS, 375 mM Tris pH 8.8) and transferred to nitro-
cellulose membrane (Protran Nitrocellulose, SpS,
Germany). Anti-I-mfa rabbit serum was raised
against a MBP-I-mf fusion protein (amino acids 1^
135). Extensive Western analysis con¢rmed that anti-
I-mf recognized I-mf isoforms (L. Snider, N. Lipnick
and N. Kraut, unpublished results). The immuno-
complexes were then detected using the ECL-Plus
Western blotting detection system (Amersham Life
Science, UK).
2.6. Statistical evaluation
Data were expressed as the mean þ S.E.M. based
on three independent experiments. For statistical
evaluation, data were compared using Mann^Whit-
ney’s U-test and P6 0.05 was considered signi¢cant.
3. Results
3.1. Osteoblastic MC3T3E1 cells express I-mfa
To examine whether I-mfa is expressed in osteo-
blastic MC3T3E1 cells, we performed RT-PCR anal-
yses (Fig. 1a). We also investigated whether I-mfa
expression could be regulated in these cells by local
and systemic regulators whose receptors are ex-
pressed in osteoblasts. Among the major cytokines
and hormones investigated, 1,25-dihydroxyvitamin
D3 speci¢cally enhanced the abundance of I-mfa
mRNA in MC3T3E1 cells (Fig. 1a,b). A relatively
low level of basal I-mfa mRNA expression was de-
tected by Northern blot analysis in which 30 Wg of
total RNA were loaded in each lane (Fig. 1c), and
enhancement of I-mfa mRNA levels by 1,25-dihy-
droxyvitamin D3 was also detected (Fig. 1c,d).
Such an enhancing e¡ect on I-mfa expression was
not observed when the cells were treated with other
local and systemic calciotropic factors, including
BMP2, basic FGF, TGF-L, retinoic acid, IL-1, IL-
6, TNF-K, PTH, dexamethasone and TPA (Fig. 2).
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1,25-Dihydroxyvitamin D3 enhancement of I-mfa
mRNA levels was observed within 24 h and lasted at
least up to 48 h (Fig. 3). In Fig. 3, the control band
intensity of I-mfa (lane 1) appears to be relatively
high compared to that in other experiments (Fig. 1,
lanes 1 and 2, Fig. 5, lane 1). This is basically due to
the di¡erence in the conditions used to take pictures
of ethidium bromide stained agarose gel plates, as
the band intensity of GAPDH in lane 1 in Fig. 3 is
also high compared to that in lanes 1 and 2 in Fig. 1
and in lane 1 in Fig. 5. 1,25-Dihydroxyvitamin D3
enhancement of I-mfa expression was dose depen-
dent starting at 10310 M and was maximal at 1039
M (Fig. 1a). To examine the vitamin D3 regulation
of I-mfa protein production, MC3T3E1 cells were
cultured in the absence (vehicle, Fig. 4, lanes 1 and
2; these samples were prepared from independent
cultures) or the presence of 1,25-dihydroxyvitamin
D3 (1038 M, Fig. 4, lanes 3 and 4; these samples
were prepared from independent cultures) for 24 h.
Western blot analysis of I-mfa was performed using
isoform speci¢c anti-I-mfa antibody that recognizes
only I-mfa. Western blot analysis indicated that I-
mfa protein was detected in the control MC3T3E1
Fig. 1. Dose dependence of vitamin D3 enhancement of I-mfa mRNA expression in MC3T3E1 cells. (a) MC3T3E1 cells were cultured
in the presence or absence of 1,25-dihydroxyvitamin D3 at the indicated concentrations for 24 h. 100 ng of total RNA were reverse
transcribed and ampli¢ed using the Titan One-Tube RT-PCR kit. One fourth of the reaction mixture was fractionated on a 2% aga-
rose gel and visualized by UV. Quantitation was conducted as described in Section 2. M, DNA size markers (xX174/HincII digest).
(b) The I-mfa mRNA level was normalized against that of GAPDH and values of relative band intensity compared to the control I-
mfa expression level in the absence of vitamin D3 are illustrated. The data represent mean values of relative band intensity and stan-
dard errors based on three independent RT-PCR experiments. An asterisk indicates that the di¡erence is statistically signi¢cant
(P6 0.05). (c) 30 Wg of the same RNA samples prepared as described in panel a were fractionated and blotted onto nylon membrane.
Northern blot analysis of I-mfa was performed as described in Section 2. By Northern blot analysis, I-mfa transcripts (1.9 kb in size)
were detected at a low level in MC3T3E1 cells and were strongly induced when MC3T3E1 cells were cultured in the presence of 1,25-
dihydroxyvitamin D3 (1038 M) for 24 h. 18S rRNA levels serve as control. The data represent one of three independent experiments
with similar results. (D) Statistical evaluation of Northern blot analysis was conducted as described in Section 2. The I-mfa mRNA
level was normalized against that of 18S ribosomal RNA which was visualized by ethidium bromide staining and values of relative
band intensity compared to the control I-mfa expression level in the absence of vitamin D3 are shown. The data represent mean val-
ues of relative band intensity and standard errors based on three independent Northern blot analyses. The asterisk indicates that the
di¡erence is statistically signi¢cant (P6 0.05).
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cells at low levels (Fig. 4, lanes 1 and 2). The results
of two separate experiments indicated that on aver-
age a 7-fold induction of I-mfa levels was observed
after vitamin D treatment (Fig. 4, lanes 3 and 4).
These 40 kDa bands were not detected by non-im-
mune serum. The bands were detected in MC3T3E1
cells in which I-mfa was overexpressed, indicating the
speci¢city of I-mfa antibody (data not shown).
We then examined whether any cross-talk or syn-
ergy exists between local or systemic signaling medi-
ators and 1,25-dihydroxyvitamin D3 with regard to
the regulation of I-mfa expression. As shown in Fig.
5, 1,25-dihydroxyvitamin D3 enhancement of I-mfa
expression was similar regardless of the co-treatment
with another di¡erentiation modulator, TGF-L. We
also observed that vitamin D3 enhancement of I-mfa
expression was similar in the presence of dexametha-
sone, retinoic acid or BMP (data not shown). These
data further indicated the speci¢city of the 1,25-dihy-
droxyvitamin D3 signaling pathway in I-mfa regula-
tion.
Fig. 2. Vitamin D3 enhances I-mfa mRNA level in MC3T3E1 cells. MC3T3E1 cells were incubated for 24 h in the presence or ab-
sence (control) of cytokines and hormones indicated in the ¢gure. After treatment, total RNA was extracted and the expression level
of I-mfa mRNA was measured by RT-PCR. GAPDH (452 bp) was used as PCR control. Note that in this experiment, the second
PCR cycle number for GAPDH was 25 so that its band intensity was higher than that in other experiments. bFGF (basic FGF) 10
ng/ml; TGF-L 4 ng/ml; D3 (1,25-dihydroxyvitamin D3) 1038 M; RA (retinoic acid) 1036 M; IL1-K 10 ng/ml; IL-6 10 ng/ml; TNF-K
10 ng/ml; PTH 1037 M; TPA 1037 M; Dex (dexamethasone) 1037 M; M, DNA size markers (xX174/HincII digest).
Fig. 3. Time dependence of the vitamin D3 enhancement of I-mfa expression in MC3T3E1 cells. (a) MC3T3E1 cells were incubated in
the presence (+) or absence (3) of 1,25-dihydroxyvitamin D3 (1038 M) for 1 or 2 days. An aliquot of 100 ng of total RNA was re-
verse transcribed and ampli¢ed using the Titan One-Tube RT-PCR kit. One fourth of the reaction mixture was fractionated on a 2%
agarose gel and visualized by UV. M, DNA size markers (xX174/HincII digest). (b) Quantitation was conducted as described in Sec-
tion 2. The I-mfa mRNA level was normalized against that of GAPDH and values of relative band intensity compared to the control
I-mfa expression level in the absence of vitamin D3 are shown. The data represent mean values of relative band intensity and standard
errors based on three independent RT-PCR experiments. An asterisk indicates that the di¡erence is statistically signi¢cant (P6 0.05).
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3.2. 1,25-Dihydroxyvitamin D3 enhancement of I-mfa
gene expression was blocked by an inhibitor for
transcription without requirement for new protein
synthesis
To elucidate the mode of 1,25-dihydroxyvitamin
D3 actions on I-mfa gene expression, we treated
MC3T3E1 cells with 1,25-dihydroxyvitamin D3 in
the presence or absence of an RNA polymerase in-
hibitor, DRB, or a protein synthesis inhibitor, CHX.
These inhibitors were added to the cultures 15 min
before the initiation of 1,25-dihydroxyvitamin D3
treatment. By treatment with CHX, the basal I-mfa
expression level was decreased (almost equal by DRB
and 50% decrease by CHX), but the e¡ect of 1,25-
dihydroxyvitamin D3 on the increment of the I-mfa
mRNA level was still observed in the presence of
CHX, whereas it was completely abolished by DRB
(Fig. 6).
We further analyzed the e¡ects of 1,25-dihydroxy-
vitamin D3 on I-mfa mRNA stability. DRB was
added to the culture medium 15 min before the ini-
tiation of 1,25-dihydroxyvitamin D3 treatment. After
0, 6 and 18 h, total RNA was extracted and sub-
jected to RT-PCR analysis. At no time point did
1,25-dihydroxyvitamin D3 alter the I-mfa mRNA
level (data not shown). These observations suggest
that 1,25-dihydroxyvitamin D3 enhances I-mfa gene
expression at least in part via an event blocked by
the transcription inhibitor without requirement for
new protein synthesis.
Fig. 4. Vitamin D3 enhancement of I-mfa protein level in
MC3T3E1 cells. MC3T3E1 cells were cultured in the absence
(vehicle, lanes 1 and 2, these samples were prepared from inde-
pendent cultures) or in the presence of 1,25-dihydroxyvitamin
D3 (1038 M, lanes 3 and 4, these samples were prepared from
independent cultures) for 24 h. 10 Wg of total cell lysate was
fractionated and blotted onto nitrocellulose membrane. Western
blot analysis of I-mfa was performed as described in Section 2
using isoform speci¢c anti-I-mfa antibody that recognizes only
I-mfa. The asterisk indicates non-speci¢c bands. The data repre-
sent one of two experiments with similar results.
Fig. 5. Vitamin D3 enhancement of I-mfa expression is not sig-
ni¢cantly altered in the presence of TGF-L. MC3T3E1 cells
were treated for 24 h with 1,25-dihydroxyvitamin D3 in the
presence or absence of TGF-L 4 ng/ml. 100 ng of total RNA
was reverse transcribed and ampli¢ed using the Titan One-Tube
RT-PCR kit. One fourth of the reaction mixture was fractionat-
ed on a 2% agarose gel and visualized by UV. M, DNA size
markers (xX174/HincII digest). (b) Quantitation was conducted
as described in Section 2. The I-mfa mRNA level was normal-
ized against that of GAPDH and values of relative band inten-
sity compared to the control I-mfa expression level in the ab-
sence of vitamin D3 (relative scale = 1) are shown. Bar graphs
represent mean values of the band intensity of two independent
experiments and individual values are indicated as circles. Open
and closed circles indicate values from two independent experi-
ments, respectively.
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3.3. I-mfa expression was also observed in primary
mouse calvaria cells
To test the generality of the observation on I-mfa
mRNA expression and its regulation by 1,25-dihy-
droxyvitamin D3 in osteoblast-like MC3T3E1 cells,
we examined osteoblast-enriched cells isolated from
newborn mouse calvariae. Similarly to MC3T3E1
cells, I-mfa expression at a relatively low level was
also observed in primary mouse calvaria cells and
1,25-dihydroxyvitamin D3 enhanced I-mfa expres-
sion in these cells (Fig. 7a,b). We also examined oth-
er osteoblast-like cells, rat osteosarcoma-derived
ROS17/2.8, which also express many di¡erentiation-
associated genes and form bone when implanted in
vivo. I-mfa mRNA was also expressed at relatively
low levels and its expression was enhanced by 1,25-
dihydroxyvitamin D3 (data not shown). In ROS17/
2.8 cells, 1,25-dihydroxyvitamin D3 was again the
speci¢c regulator of I-mfa expression as other mod-
ulators (BMP, basic FGF, TGF-L, retinoic acid, IL-
1, IL-6, TNF-K, PTH, dexamethasone and TPA) did
not alter I-mfa mRNA levels (data not shown).
4. Discussion
Here we show that I-mfa is expressed in osteo-
blasts and that a calciotropic hormone, 1,25-dihy-
droxyvitamin D3, speci¢cally enhances its expression
in these cells.
I-mfa may interact with and modulate the function
of certain HLH type transcription factors expressed
in osteoblast-like cells. Regulatory regions of the
genes encoding di¡erentiation-associated markers,
such as type I collagen [12], osteocalcin, alkaline
phosphatase and osteopontin, contain E-box motifs.
Forced expression of scleraxis, a positive type bHLH
transcription factor [13], enhanced the expression of
osteopontin in ROS17/2.8 cells [6]. About 1 kb of the
mouse osteopontin promoter contains several E-
boxes. We have recently found that I-mfa can inter-
act with scleraxis in a yeast two-hybrid assay and
counteracts the activity of scleraxis on synthetic
scleraxis-dependent reporter constructs (containing
idealized scleraxis-binding sites) in transfection ex-
periments ([14]; N. Kraut, unpublished results).
Since the overall action of vitamin D is to upregulate
osteopontin expression, it appears that 1,25-dihy-
droxyvitamin D3 activation of osteopontin via its
VDRE is more potent than its simultaneous activa-
tion of I-mfa as a negative regulator. These bidirec-
tional activities of 1,25-dihydroxyvitamin D3 may
contribute to the balanced regulation of osteoblastic
phenotype expression.
Vitamin D3 acts to increase blood calcium levels in
vivo. Clinical studies also indicate e⁄cacy of vitamin
D3 in reducing osteoporotic fractures [15,16]. In ad-
dition to its action on intestinal calcium absorption,
vitamin D3 also acts on bone cells directly [17]. 1,25-
Dihydroxyvitamin D3 enhancement of I-mfa could
prevent myoblastic di¡erentiation of mesenchyme-
derived cells and thus may increase the cell popula-
tions directed to osteoblastic lineage. Alternatively, if
I-mfa acts to suppress yet unknown positive HLH
Fig. 6. Vitamin D3 enhancement of I-mfa mRNA expression is
blocked by DRB but not by CHX. MC3T3E1 cells were treated
for 24 h with 1,25-dihydroxyvitamin D3 (1038 M) in the pres-
ence or absence of the RNA polymerase inhibitor DRB (25 Wg/
ml), or the protein synthesis inhibitor CHX (10 Wg/ml). Inhibi-
tors were added 15 min prior to the treatment with vitamin D3.
Total RNA was extracted and the I-mfa expression level was
measured by RT-PCR. Quantitation was conducted as de-
scribed in Section 2. I-mfa mRNA levels were normalized
against those of GAPDH and values of relative band intensity
compared to the control I-mfa expression level in the absence
of vitamin D3 but in the presence of inhibitors or vehicle are
shown. The data represent mean values of relative band inten-
sity and standard errors based on three independent RT-PCR
experiments. An asterisk indicates that the di¡erence is statisti-
cally signi¢cant (P6 0.05).
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regulators in osteoblasts, it could contribute to the
increase of a pool of osteoblastic progenitors. We
have reported that 1,25-dihydroxyvitamin D3 sup-
presses expression of Id-1 and HES-1, which act as
negative regulators for HLH type transcription fac-
tors in osteoblast-like cells [18,7]. 1,25-Dihydroxyvi-
tamin D3 may act as both a suppressor and an acti-
vator of these negative regulators to maintain the
balance of negative transcriptional activities; how-
ever, these points need further investigation on the
function of I-mfa relative to the functions of other
negative regulators.
Recent knockout experiments also indicate that I-
mfa may be involved in a certain part of bone for-
mation [14]. These observations further suggest that
I-mfa may play a role, at least in part, in the deter-
mination of the fate of skeletal cells.
In summary, we showed that I-mfa is expressed in
osteoblasts and that its level is under the speci¢c
control of a calciotropic hormone, 1,25-dihydroxyvi-
tamin D3.
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